Is BPC-157 Legal in Pennsylvania? How to Access It Legally

What the federal status of BPC-157 actually is

BPC-157 is a synthetic 15-amino-acid peptide with a molecular weight of about 1419.5 g/mol, made either as a free base or as an acetate salt; FDA treats those as two different bulk substances [1]. It is not an FDA-approved drug. No FDA-approved drug contains it, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

Under FDA's compounding framework, state-licensed pharmacists and physicians may use a bulk substance only when it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's bulk-substance list, along with the other applicable requirements [9]. BPC-157 meets none of those, and it sits in none of the three interim categories FDA uses while that list is being built [1][2]. Category 1 is the group FDA says it generally will not act against compounders for; BPC-157 is not in it [2].

Why it came off the safety-risk table, and why that is not clearance

BPC-157 sat in category 2 — substances FDA says may present significant safety risks when compounded — from September 2023 until April 22, 2026 [6][4]. It moved to a separate 'nominated but withdrawn' table on FDA's significant-safety-risk page after the groups that nominated it withdrew their nominations [6]. That page still carries FDA's concerns: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration,' may have problems with peptide-related impurities and characterization of the active ingredient, and FDA 'has identified no, or only limited, safety-related information for the proposed routes of administration' [6]. Coming off the category 2 table was not a finding of safety [6].

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the bulk-substance list (news reports give the vote as 8 to 6 with 1 abstention), against the recommendation of FDA's own reviewers [10][1]. Those reviewers had proposed that it not be added: it is not well characterized chemically, there is little information on its safety and immunogenicity, the evidence for ulcerative colitis was insufficient, and several approved drugs already treat that condition [1]. The committee's vote is advice only, and adding a substance to the list requires formal rulemaking — a proposed rule, public comment and a final rule [10][4].

The October 2026 draft HHS policy

On October 28, 2026, HHS filed a notice announcing a draft enforcement-discretion policy for compounding with six peptides, BPC-157 among them, scheduled for Federal Register publication on October 30, 2026, with public comments open for two weeks after publication [3][4]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA develops its list through rulemaking, if the policy's conditions are met [3][4].

The BPC-157 conditions in the draft are specific [4]:

• BPC-157 acetate only
• subcutaneous, intramuscular, oral or topical forms; nasal, rectal and intravenous forms are not listed
• a single active ingredient
• bulk substance from an FDA-registered manufacturer, with a valid certificate of analysis meeting a peptide testing standard
• a label reading 'This is a compounded drug product. Not for resale.'
• a patient-specific prescription
• serious adverse events and quality problems reported to FDA MedWatch
• an FDA 510(k)-cleared syringe as the only co-packaged device
• for oral forms, documentation of adequate bioavailability

It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities; BPC-157 is also not on FDA's list for outsourcing facilities, last updated March 21, 2025 [3][4][7]. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public,' and HHS may revisit the policy, for example if a safety signal or product quality issue appears [3]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [11].

Pennsylvania: the state layer

Pennsylvania's Board of Pharmacy regulates the practice of pharmacy through licensure, registration, certification and discipline, and decides case by case whether a licensee departed from an ethical or quality standard of the profession [5]. The Board's page lists the state's pharmacy law, Act 699 of 1961, and its compounding regulations [5].

The draft HHS policy applies to state-licensed pharmacies, federal facilities and licensed physicians [3][4]. Whether a given Pennsylvania pharmacy compounds BPC-157 is subject to that pharmacy's licensing obligations under the Board [5].

Which forms are covered, and what is known about them

The draft policy covers BPC-157 acetate in subcutaneous, intramuscular, oral and topical forms; nasal, rectal and intravenous forms are not listed [4]. FDA found no human studies of BPC-157 given by mouth, subcutaneous injection, nasal spray or skin, and no human pharmacokinetic data for those routes [1]. After rectal enemas in two early studies, BPC-157 was mostly not detectable in blood, and FDA judged that it appears not to be absorbed systemically by that route [1].

What human evidence exists

The human evidence FDA reviewed is small; it identified five clinical studies, one of them a two-person pilot [1]. A 2026 systematic review searched to June 1, 2026 and found three studies covering 30 patients, all of poor methodological quality, with overall certainty of evidence rated very low; the reviewers concluded that BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [12].

The largest of those was a chart review at one Florida clinic: 17 patients, 16 reached by phone, 12 given intra-articular BPC-157 alone and 4 with thymosin beta-4; 11 of the 12 BPC-157-only patients reported significant improvement, with no control group and no validated outcome tools [13]. A pilot in 12 women with interstitial cystitis reported complete symptom resolution in 10 of them and about 80% resolution in the other 2 after a single procedure injecting 10 mg around the bladder wall; it was single-arm and patient-rated [14]. A two-person intravenous pilot reported no measurable change in tested heart, liver, kidney, thyroid or glucose markers [15].

Safety signals to know about

FDA's search of its adverse-event database through December 4, 2025 turned up three reports, all for injectable BPC-157: injection-site redness and swelling lasting nine days (the patient also used compounded thymosin), shortness of breath leading to an emergency room visit, and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 product [1]. FDA said it cannot tell whether BPC-157 caused these [1].

FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1]. In 28-day intramuscular animal studies it shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels; longer studies and cancer-risk studies were not available [1].

Athletes

WADA's Prohibited List names BPC-157 in class S0, non-approved substances, and it is prohibited at all times, in and out of competition; the 2026 List has been in force since January 1, 2026 [8]. It was first named under S0 in the 2022 List and remains named in the 2027 List [16][17].

Products sold as research chemicals

FDA noted websites selling BPC-157, alone or blended with TB-500, as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use' [1]. Those products are not FDA-approved drugs [1].